Among the critical components of long-term care for certain rare genetic metabolic disorders is specialised nutrition, which is often a therapeutic necessity, rather than a dietary or lifestyle preference for many patients.

For individuals diagnosed with inborn errors of metabolism (IEM), strict dietary management forms part of lifelong treatment. These patients often require carefully calibrated specialised nutritional formulations to prevent metabolic complications, as these conditions could impair the body's ability to process certain nutrients.

Therefore, securing stable, reliable access to specialised nutrition is vital for more resilient care management of rare disease patients.

When Nutrition Becomes Essential Support

Unlike conventional dietary support, specialised nutrition for rare metabolic diseases is designed to meet highly specific biochemical requirements. Even minor disruptions in availability can affect disease management, particularly for paediatric patients whose growth and neurological development depend on precise dietary control.

According to Dr Ngu Lock Hock, Clinical Genetics Consultant and Head of the Genetics Department of Hospital Kuala Lumpur, patients with genetic metabolic disorders in Malaysia have historically depended heavily on imported specialised nutrition products.

"Many metabolic formulas and specialised dietary substitutes were sourced from overseas manufacturers. While they provided clinically necessary support, dependence on imports meant exposure to both supply vulnerabilities and higher costs," he said.

Imported formulations are often subject to currency fluctuations, transportation expenses, and international production constraints, and geopolitical tensions, all of which can contribute to an increased financial burden for families and healthcare institutions.

In addition, disruptions in global manufacturing or shipping logistics could further create uncertainty for caregivers managing lifelong conditions, complicating long-term care planning and continuity of support.

"In metabolic care, consistency is critical. Any interruption in access to specialised nutrition,  whether due to supply delays or affordability challenges, creates stress for caregivers and potential clinical risk for patients," he added.

Addressing Supply Vulnerability and Building Local Production Capacity

Malaysia's reliance on imported specialised metabolic nutrition has reflected global patterns, where specialised formulations are often concentrated among a small number of international producers.

However, recent global supply chain disruptions have highlighted the need for stronger domestic resilience in essential healthcare components. While pharmaceutical supply security is frequently discussed, specialised nutrition, particularly for rare genetic metabolic disorders, remains much less visible in healthcare ecosystem resilience conversations.

The recently launched National Policy for Rare Diseases in Malaysia now provides a structured roadmap for strengthening Malaysia's rare disease healthcare ecosystem, including improving access to essential services and long-term support. Within this context, building local production capacity in specialised metabolic nutrition represents an essential area of system reinforcement.

In response to this, local production initiatives have begun to take shape among homegrown healthcare solutions providers to develop locally produced specialised nutrition solutions tailored for genetic metabolic disorders. Among them are protein-free specialised nutrition products manufactured in Malaysia under VALENS, a specialised nutrition brand by homegrown pharmaceutical and consumer health company Pharm-D Health Science.

Such local production initiatives aim to complement existing imported options by reducing dependence on singular foreign supply chains and improving domestic responsiveness to clinical needs, as local production can shorten supply timelines, enhance distribution stability, and allow closer collaboration between manufacturers and healthcare providers managing rare genetic metabolic conditions in Malaysia.

Industry observers note that strengthening domestic capability does not replace international innovation but rather creates a more balanced and resilient healthcare ecosystem for rare disease patients.

Supporting Long-Term Sustainability

For families living with rare genetic metabolic disorders, care management extends beyond hospital settings into daily life. Parents and caregivers meticulously monitor dietary intake, calculate nutrient allowances, and maintain strict adherence to prescribed nutritional regimens.

More stable access to specialised nutrition, therefore, plays a direct role in maintaining clinical stability and quality of life.

As Malaysia advances its rare disease agenda, reinforcing continuity of specialised nutrition supply aligns with broader goals of healthcare sustainability and system resilience.

Dr Ngu emphasised that multi-stakeholder collaboration remains central to this progress.

"Policy direction, clinical expertise, patient advocacy and responsible industry participation must work together to strengthen rare disease care. Building sustainable access to specialised nutrition is part of that collective responsibility," he said.

Towards a More Resilient Rare Disease Ecosystem

As Malaysia advances its rare disease healthcare agenda, experts emphasise that healthcare resilience must extend beyond pharmaceuticals and include other essential care components, such as specialised nutrition.

Strengthening domestic production capability in specialised nutrition, therefore, represents a much-needed practical step toward reinforcing that commitment.

As local capability continues to develop alongside global partnerships, Malaysia's rare disease healthcare ecosystem stands to benefit from greater stability, responsiveness, and preparedness, which in turn supports Malaysian patients and families of the rare disease community.

About Pharm-D Health Science (PDHS)  

Founded in 2001, Pharm-D Health Science (PDHS) is a pharmaceutical and consumer health company specialising in specialised medicines, pharmaceuticals, healthcare and consumer health products. With a steadfast commitment to pioneering research, development, and manufacturing, PDHS offers a comprehensive array of solutions, including medications, over-the-counter medications, specialised nutrition, health supplements, and medical devices. Notably, PDHS is also a pioneer in postbiotics research and supply in Malaysia.

Beyond pharmaceuticals, the company provides healthcare and consumer health solutions under trusted house brands such as VALENS, ELDON, Lang Bragman, MedSkin, Reflux-G, Retane, and more. Ultimately, Pharm-D Health Science's dedication to scientific excellence and holistic healthcare is driven by the mission to make health and wellbeing accessible for all with science.

For more information about Pharm-D Health Science, please visit https://www.pharmdhs.com/

With the theme "More Than You Can Imagine", this global initiative aims to highlight the challenges faced by rare disease patients, including delays in diagnosis, limited access to genetic testing, and the high cost of treatment.

Speaking at the event, Dato' Dr. Harikrishna a/l K. Ragavan Nair, Director of Hospital Kuala Lumpur, emphasized the need for stronger policies and diversified funding options to improve access to genetic testing and treatment for rare disease patients.

"Rare diseases impact more individuals than we realize – 1 in 17 people worldwide. This means that each of us likely knows someone living with a rare disease, whether they are a family member, a colleague, or a friend. Today's event is not just a celebration but a movement that brings together healthcare professionals, researchers, policymakers, patient advocacy groups, and industry leaders to work towards better diagnosis, treatment, and quality of life for these patients," said Dato' Dr. Harikrishna.

This year's Rare Disease Day celebration emphasizes the need for equity in healthcare, support, and opportunities for the rare disease community in Malaysia. With many Malaysians affected by rare diseases, ensuring fair access to timely diagnosis, treatment, and social inclusion is more crucial than ever.

Head of the Genetics Department Hospital Kuala Lumpur, Dr. Ngu Lock Hock, further underscored the importance of collective efforts in supporting rare disease patients. "Malaysia officially defined rare diseases in 2020 as life-threatening or chronically debilitating conditions affecting fewer than 1 in 4,000 individuals. Over 70% of rare diseases are genetic, and many cases involve children. At HKL's Genetics Department, we have provided consultations to over 10,000 families and conduct around 1,000 genetic tests annually.

These efforts are made possible through the strong support and commitment of the Ministry of Health, Hospital Kuala Lumpur, Hospital Tunku Azizah, as well as collaborations with various departments, NGOs, patient organizations, industry partners, and the private sector. Moving forward, strengthening these collaborations will be key to improving timely diagnosis and expanding access to treatment for rare disease patients," he shared.

As part of the initiative to improve rare disease awareness, the event also marked the launch of three new books tailored for patients and caregivers: "Buku Resipi Rendah Protein untuk Pesakit Inherited Metabolic Disorders (IMD)", produced through a collaboration between HKL's dietitians and the Genetics Department, with printing support from Pharm-D Health Science. "Pengembaraan Morquio A" and "Mia & Penjelajahan MPS 6", engaging comic-style books that are designed to help children with Morquio Syndrome and Mucopolysaccharidosis type 6 (MPS VI) to better understand their condition.

Pharm-D Health Science supported this event through its JARANG Program, a corporate social responsibility (CSR) initiative aimed to raise awareness, provide support, and empower individuals and families affected by rare diseases in Malaysia. Mr. Wong Chin Cheang, Managing Director of Pharm-D Health Science, expressed the company's commitment to bridging healthcare gaps in the rare disease community.

"Pharm-D Health Science believes in empowering the rare disease community through innovation and collaboration. Through the JARANG Program, we are dedicated to supporting awareness campaigns like today's event. Together, we can drive meaningful change and make a lasting impact on patients' lives," said Mr. Wong.

A highlight of the event was the mock cheque handover ceremony, where AGTC Genomics sponsored and Pharm-D Health Science supported the contribution of RM75,000 worth of whole exome sequencing (WES) tests for underprivileged patients. This funding will enable critical genetic testing, which is often a significant financial burden for affected families.

As the event concluded, Dr. Ngu called for continued collaboration to improve the lives of rare disease patients. "Together, we can make a difference – by listening, understanding, and taking action to bring hope to the rare disease community."